Pharmacological Inhibition of Poly(ADP-Ribose) Polymerases Improves Fitness and Mitochondrial Function in Skeletal Muscle

[1]  E. Mercken,et al.  Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging , 2013, Cell.

[2]  N. Curtin,et al.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. , 2013, Molecular aspects of medicine.

[3]  J. Denu,et al.  Circadian Clock NAD+ Cycle Drives Mitochondrial Oxidative Metabolism in Mice , 2013, Science.

[4]  L. Guarente,et al.  The NAD+/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling , 2013, Cell.

[5]  J. Auwerx,et al.  Pharmacological approaches to restore mitochondrial function , 2013, Nature Reviews Drug Discovery.

[6]  Robert W. Williams,et al.  Mitonuclear protein imbalance as a conserved longevity mechanism , 2013, Nature.

[7]  Kaustabh Singh,et al.  Sirtuin 1-mediated Effects of Exercise and Resveratrol on Mitochondrial Biogenesis* , 2013, The Journal of Biological Chemistry.

[8]  J. Carmichael,et al.  Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery , 2013, Investigational New Drugs.

[9]  C. Cantó,et al.  The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. , 2012, Cell metabolism.

[10]  M. Westerterp-Plantenga,et al.  Augmenting muscle diacylglycerol and triacylglycerol content by blocking fatty acid oxidation does not impede insulin sensitivity , 2012, Proceedings of the National Academy of Sciences.

[11]  H. Ellingsgaard,et al.  ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high‐fat diet and impairs adipocyte function and differentiation , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  Johan Auwerx,et al.  Sirtuins as regulators of metabolism and healthspan , 2012, Nature Reviews Molecular Cell Biology.

[13]  W. Kraus,et al.  On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. , 2012, Genes & development.

[14]  J. Auwerx,et al.  Targeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD+? , 2012, Pharmacological Reviews.

[15]  Evan G. Williams,et al.  NCoR1 Is a Conserved Physiological Modulator of Muscle Mass and Oxidative Function , 2011, Cell.

[16]  Amy E. Knapp,et al.  Sirtuin 1 (SIRT1) Deacetylase Activity Is Not Required for Mitochondrial Biogenesis or Peroxisome Proliferator-activated Receptor-γ Coactivator-1α (PGC-1α) Deacetylation following Endurance Exercise* , 2011, The Journal of Biological Chemistry.

[17]  J. Auwerx,et al.  PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. , 2011, Cell metabolism.

[18]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[19]  M. Patti,et al.  The role of mitochondria in the pathogenesis of type 2 diabetes. , 2010, Endocrine reviews.

[20]  Robert V Farese,et al.  Sirt3 Regulates Fatty Acid Oxidation via Reversible Enzyme Deacetylation Hhs Public Access Supplementary Material , 2022 .

[21]  C. Toniatti,et al.  Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. , 2009, Journal of medicinal chemistry.

[22]  E. Shoubridge,et al.  Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome , 2009, Nature Genetics.

[23]  J. Takahashi,et al.  Circadian Clock Feedback Cycle Through NAMPT-Mediated NAD+ Biosynthesis , 2009, Science.

[24]  P. Puigserver,et al.  AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity , 2009, Nature.

[25]  Philippe Pierre,et al.  SUnSET, a nonradioactive method to monitor protein synthesis , 2009, Nature Methods.

[26]  P. Dedon,et al.  Quantification of DNA damage products resulting from deamination, oxidation and reaction with products of lipid peroxidation by liquid chromatography isotope dilution tandem mass spectrometry , 2008, Nature Protocols.

[27]  T. Sorg,et al.  Genetic background determines metabolic phenotypes in the mouse , 2008, Mammalian Genome.

[28]  R. Boushel,et al.  Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle , 2007, Diabetologia.

[29]  L. Scorrano,et al.  Organelle isolation: functional mitochondria from mouse liver, muscle and cultured filroblasts , 2007, Nature Protocols.

[30]  P. Puigserver,et al.  Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α , 2006, Cell.

[31]  A. Sauve,et al.  NAD metabolism and sirtuins: Metabolic regulation of protein deacetylation in stress and toxicity , 2006, The AAPS Journal.

[32]  M. Zeviani,et al.  Clinical and molecular findings in children with complex I deficiency. , 2004, Biochimica et biophysica acta.

[33]  P. Chambon,et al.  Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse , 2003, The EMBO journal.

[34]  K. Yasuda,et al.  A Defect in the Cytochrome b Large Subunit in Complex II Causes Both Superoxide Anion Overproduction and Abnormal Energy Metabolism in Caenorhabditis elegans * , 2001, The Journal of Biological Chemistry.

[35]  Reynaldo Sequerra,et al.  High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP , 2000, Nature Genetics.

[36]  J. Melki,et al.  Gene targeting restricted to mouse striated muscle lineage. , 1999, Nucleic acids research.

[37]  P. Chambon,et al.  Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  N. Manning,et al.  A comparison of [9,10-3H]palmitic and [9,10-3H]myristic acids for the detection of defects of fatty acid oxidation in intact cultured fibroblasts , 1990, Journal of Inherited Metabolic Disease.

[39]  P. Das,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[40]  Robert W. Williams,et al.  A new set of BXD recombinant inbred lines from advanced intercross populations in mice , 2004, BMC Genetics.